Article
The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Dec 2025
Ma Wenyan, Zhao Baicheng, Lang Yukuan, Liu Zhirui, Che Zhimei, Yan Bo, Yao Feng, Yang Haitang, Chu Tianqing
Abstract excerpt
INTRODUCTION: Adjuvant chemotherapy or/and adjuvant Epidermal Growth Factor Receptor tyrosine kinase inhibitor (EGFR-TKI) therapy are commonly used to treat completely resected non-small cell lung cancer (NSCLC) with EGFR mutations in IB-IIIA stages. However, there is limited evidence regarding the comparative effectiveness of adjuvant EGFR-TKI, adjuvant chemotherapy and chemotherapy combination EGFR-TKI in terms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.